IFNβ SENSITIZES PANCREATIC TUMOR CELLS TO GEMCITABINE BY MODULATING AUTOPHAGY

SANTIAGO BEHR; DANIELA POODTS; DANIEL GRASSO; MARIA NOÉ GARCIA; ELIDA ALVAREZ; DANIELA L. PAPADEMETRIO

Mar del Plata

Congreso; Reunión Anual de Biociencias 2022; 2022

Sociedad Argentina de Investigación Clínica

Infiltrating pancreatic ductal adenocarcinoma (PDAC) accounts for over 95% of all exocrine pancreatic malignancies, with a median survival of only 4–6 months. Despite its poor efficacy, Gemcitabine is a first line agent for PDAC treatment. Previously, we identified that autophagy is involved in gemcitabine chemoresistance. Now, we propose to evaluate the effect of IFNβ on autophagic flux and its ability to sensitize MIAPaCa-2 and PANC-1 cell lines to the effects of gemcitabine. The treatment for 48h with IFNβ in a dose of 1000UI/ml showed a dose and time dependent inhibition of cellular proliferation, by IFNβ by 3H-timidine incorporation (67.3±5.1% and 52.3±1.9% for MIAPaCa-2 and PANC-1 cells respectively (p